<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)
(AMENDMENT NO. _2_)1
AUTOIMMUNE INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
052776 10 1
(CUSIP Number)
FEBRUARY 14, 2000
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
- -----------------------
1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subjevt class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, SEE the
NOTES).
<PAGE>
- ------------------------------ -----------------------------
CUSIP NO. 052776 10 1 13G PAGE 2 OF 8 PAGES
- ------------------------------ ------------------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BIOTECHNOLOGY VALUE FUND, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
- --------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
- --------- ---------------------------------------------------------------------
3 SEC USE ONLY
- --------- ---------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- -------------------------- ----- ----------------------------------------------
NUMBER SOLE VOTING POWER
OF 5 0
SHARES ----------------------------------------------
BENEFICIALLY SHARED VOTING POWER
OWNED BY EACH 6 936,609
REPORTING ----------------------------------------------
PERSON SOLE DISPOSITIVE POWER
WITH 7 0
----------------------------------------------
SHARED DISPOSITIVE POWER
8 936,609
- --------- ---------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
936,609
- --------- ---------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
- --------- ---------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.6%
- --------- ---------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
- --------- ---------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ------------------------------ ------------------------------
CUSIP NO. 052779 10 1 13G PAGE 3 OF 8 PAGES
- ------------------------------ ------------------------------
- --------- ---------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BIOTECHNOLOGY VALUE FUND II, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
- --------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
- --------- ---------------------------------------------------------------------
3 SEC USE ONLY
- --------- ---------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- -------------------------- ----- ----------------------------------------------
NUMBER SOLE VOTING POWER
OF 5 0
SHARES ----------------------------------------------
BENEFICIALLY SHARED VOTING POWER
OWNED BY EACH 6 1,304,550
REPORTING ----------------------------------------------
PERSON SOLE DISPOSITIVE POWER
WITH 7 0
----------------------------------------------
SHARED DISPOSITIVE POWER
8 1,304,550
- -------------------------- ----- ----------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,304,550
- --------- ---------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
- --------- ---------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.8%
- --------- ---------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
- --------- ---------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ------------------------------ -----------------------------
CUSIP NO. 052776 10 1 13G PAGE 4 OF 8 PAGES
- ------------------------------ -----------------------------
- --------- ---------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BVF PARTNERS L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
- --------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
- --------- ---------------------------------------------------------------------
3 SEC USE ONLY
- --------- ---------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- -------------------------- ----- ----------------------------------------------
NUMBER SOLE VOTING POWER
OF 5 0
SHARES ----------------------------------------------
BENEFICIALLY SHARED VOTING POWER
OWNED BY EACH 6 2,312,709
REPORTING ----------------------------------------------
PERSON SOLE DISPOSITIVE POWER
WITH 7 0
----------------------------------------------
SHARED DISPOSITIVE POWER
8 2,312,709
- -------------------------- ----- ----------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,312,709
- --------- ---------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
- --------- ---------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
13.9%
- --------- ---------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
- --------- ---------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ------------------------------ -----------------------------
CUSIP NO. 052776 10 1 13G PAGE 5 OF 8 PAGES
- ------------------------------ -----------------------------
- --------- ---------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BVF INC.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
- --------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
- --------- ---------------------------------------------------------------------
3 SEC USE ONLY
- --------- ---------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- -------------------------- ----- ----------------------------------------------
NUMBER SOLE VOTING POWER
OF 5 0
SHARES ----------------------------------------------
BENEFICIALLY SHARED VOTING POWER
OWNED BY EACH 6 2,312,709
REPORTING ----------------------------------------------
PERSON SOLE DISPOSITIVE POWER
WITH 7 0
----------------------------------------------
SHARED DISPOSITIVE POWER
8 2,312,709
- -------------------------- ----- ----------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,312,709
- --------- ---------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
- --------- ---------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
13.9%
- --------- ---------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IA, CO
- --------- ---------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ------------------------------ -----------------------------
CUSIP NO. 052776 10 1 13G PAGE 6 OF 8 PAGES
- ------------------------------ -----------------------------
ITEM 1(a). NAME OF ISSUER:
Autoimmune Inc. ("Autoimmune")
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
128 Spring Street
Lexington, MA 02173
ITEM 2(a). NAME OF PERSON FILING:
This Amendment to Schedule 13G is being filed on behalf of the
following persons*:
(i) Biotechnology Value Fund, L.P. ("BVF")
(ii) Biotechnology Value Fund II, L.P. ("BVF2")
(iii) BVF Partners L.P. ("Partners")
(iv) BVF Inc. ("BVF Inc.")
* Attached as Exhibit A is a copy of an agreement among
the persons filing (as specified hereinabove) that
this Amendment to Schedule 13G is being filed on
behalf of each of them.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:
The principal business office of the persons
comprising the group filing this Amendment to Schedule 13G is
located at 227 West Monroe Street, Suite 4800, Chicago, Illinois, 60606.
ITEM 2(c). CITIZENSHIP:
BVF: a Delaware limited partnership
BVF2: a Delaware limited partnership
Partners: a Delaware limited partnership
BVF Inc.: a Delaware corporation
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock.
ITEM 2(e). CUSIP NUMBER:
052776 10 1
<PAGE>
- ------------------------------ -----------------------------
CUSIP NO. 052776 10 1 13G PAGE 7 OF 8 PAGES
- ------------------------------ -----------------------------
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b) OR
(c) CHECK WHETHER THE PERSON FILING IS: ONE OF THE FOLLOWING
Not applicable as this Amendment to Schedule 13G is filed
pursuant to Rule 13d 1(c).
ITEM 4. OWNERSHIP:
The information in items 1 and 5 through 11 on the cover
pages (pp. 2 - 5) on this Amendment to Schedule 13G is hereby incorporated by
reference.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities check the following. |_|
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON:
BVF shares voting and dispositive power over the shares of the
common stock it beneficially owns with Partners. BVF2 also shares voting and
dispositive power over the shares of the common stock it beneficially owns
with Partners. Partners and BVF Inc. share voting and dispositive power over
the shares of the common stock they beneficially own with, in addition to BVF
and BVF2, certain managed accounts on whose behalf Partners, as investment
manager, purchased such shares. None of the managed accounts individually
owns more than 5% of the common stock of Autoimmune.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT
HOLDING COMPANY:
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
Not applicable.
<PAGE>
- ------------------------------ -----------------------------
CUSIP NO. 052776 10 1 13G PAGE 8 OF 8 PAGES
- ------------------------------ -----------------------------
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.
Dated: February 10, 2000
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /S/ MARK N. LAMPERT
----------------------
Mark N. Lampert
President
BIOTECHNOLOGY VALUE FUND II, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /S/ MARK N. LAMPERT
----------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /S/ MARK N. LAMPERT
----------------------
Mark N. Lampert
President
BVF INC.
By: /S/ MARK N. LAMPERT
-------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT A
AGREEMENT REGARDING JOINT FILING
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, Biotechnology Value Fund II, L.P., a Delaware limited
partnership, BVF Partners L.P., a Delaware limited partnership, and BVF Inc.,
a Delaware corporation, hereby agree and acknowledge that the information
required by the Amendment to Schedule 13G, to which this Agreement is
attached as an exhibit, is filed on behalf of each of them. The undersigned
further agree that any further amendments or supplements thereto shall also
be filed on behalf of each of them.
Dated: February 10, 2000
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /S/ MARK N. LAMPERT
-----------------------
Mark N. Lampert
President
BIOTECHNOLOGY VALUE FUND II, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /S/ MARK N. LAMPERT
-----------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /S/ MARK N. LAMPERT
------------------------
Mark N. Lampert
President
BVF INC.
By: /S/ MARK N. LAMPERT
-----------------------
Mark N. Lampert
President
